Klin Onkol 2000; 13(6): 173-176.
Summary: In developed countries, colorectal cancer is the third most common cancer,after lung and prostate cancer in men, and second after breast cancer in women. It is recognized that chemotherapy offers benefits for patients with advanced colorectal carcinoma. Raltitrexed is an alternative to standard 5-fluorouracil for the first line chemotherapy of advanced colorectal carcinoma with the advantage of a short intravenous infusion administration in 3 weekly schedule with manageable
toxicity profile. Phase III studies have demonstrated that objective response rates are comparable for raltitrexed monotherapy and 5-FU/leucovorin regimens.Raltitrexed is a potentially attractive agent for use in combination therapy.
